Key statistics dashboard for Serina Therapeutics, Inc. (SER). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy.
Stock Data
| Price | $2.16 |
| Market Cap | $32M |
| Enterprise Value | $15.4M |
| Beta | 0.10 |
| Exchange | AMEX |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.25 |
| Price / Book | 2.06 |
| P/S | 0.00 |
| EV/EBITDA | -0.70 |
| EV/Sales | 0.00 |
| EV/FCF | -0.73 |
| P/FCF | -1.66 |
| Earnings Yield | -54.99% |
| FCF Yield | -60.08% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -222.42% |
| Return on Assets | -82.03% |
| Return on Invested Capital | -116.37% |
| Return on Capital Employed | -116.37% |
Financial Health
| Current Ratio | 6.65 |
| Quick Ratio | 6.65 |
| Cash Ratio | 6.12 |
| Debt / Equity | 0.17 |
| Debt / Assets | 12.43% |
| Net Debt / EBITDA | 0.89 |
| Interest Coverage | -117.72 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.14 |
| Cash per share | 1.41 |
| FCF per share | -1.29 |
| Tangible Book Value per share | 1.14 |
| Dividend per share | 0.00 |
Related companies: ALGS · BRNS · CVM · GNTA · GRCE · INMB · JUNS
Explore sector: Healthcare · Biotechnology
More sections of SER: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks